Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000062J1
HKD
474.20
20.6 (4.54%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
SciClone Pharmaceuticals (Holdings) Ltd.
Livzon Pharmaceutical Group, Inc.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Ocumension Therapeutics
Shandong Boan Biotechnology Co., Ltd.
Cutia Therapeutics
Lepu Biopharma Co., Ltd.
RemeGen Co., Ltd.
Everest Medicines Ltd.
InnoCare Pharma Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Why is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ?

1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
  • Poor long term growth as Operating profit has grown by an annual rate -413.15% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -18.01
2
Flat results in Dec 25
  • INTEREST(HY) At HKD 3.43 MM has Grown at 145.52%
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 45.02%, its profits have risen by 47%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
45.02%
2.96
56.04%
Hang Seng Hong Kong
8.76%
0.45
19.63%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
204.90%
EBIT Growth (5y)
-413.15%
EBIT to Interest (avg)
-18.01
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.11
Tax Ratio
87.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
17.24
EV to EBIT
-297.56
EV to EBITDA
-442.88
EV to Capital Employed
143.92
EV to Sales
42.87
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-48.37%
ROE (Latest)
-5.69%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
NET SALES(Q)

At HKD 1,212.42 MM has Grown at 103.11%

RAW MATERIAL COST(Y)

Fallen by -606.69% (YoY

CASH AND EQV(HY)

Highest at HKD 5,078.28 MM

PRE-TAX PROFIT(Q)

At HKD -209.46 MM has Grown at 65.89%

NET PROFIT(Q)

At HKD -271.39 MM has Grown at 57.69%

-6What is not working for the Company
INTEREST(HY)

At HKD 3.43 MM has Grown at 145.52%

Here's what is working for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Net Sales
At HKD 1,212.42 MM has Grown at 103.11%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely positive

Net Sales (HKD MM)

Pre-Tax Profit
At HKD -209.46 MM has Grown at 65.89%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit
At HKD -271.39 MM has Grown at 57.69%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (HKD MM)

Cash and Eqv
Highest at HKD 5,078.28 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by -606.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at HKD 56.12 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation
At HKD 56.12 MM has Grown at 6.35%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Interest
At HKD 3.43 MM has Grown at 145.52%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)